Kiniksa Pharmaceuticals International (KNSA) EV to FCF (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported EV to FCF for 9 consecutive years, with 203.1 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to FCF rose 54.83% year-over-year to 203.1; the trailing twelve-month figure through Jun 2026 stood at 52.33 (down 5.48% YoY), and the FY2025 full-year result was 43.18, down 73.81% from the prior year.
• EV to FCF climbed to 203.1 in Q2 2026 per KNSA's latest filing, from 138.48 in the prior quarter.
• Across five years, EV to FCF topped out at 3878.42 in Q1 2024 and bottomed at 1450.3 in Q3 2024.
• Historically, EV to FCF has averaged 201.67 across 5 years, with a median of 122.2 in 2023.
• The sharpest annual moves came in 2023 and 2024: EV to FCF slumped 3546.51% in 2023, then soared 489.19% in 2024.
• Over 5 years, EV to FCF stood at 160.32 in 2022, then soared by 346.85% to 395.76 in 2023, then slumped by 59.09% to 161.9 in 2024, then declined by 27.95% to 116.65 in 2025, then jumped by 74.11% to 203.1 in 2026.
• According to Business Quant data, EV to FCF over the past three periods registered 203.1, 138.48, and 116.65 for Q2 2026, Q1 2026, and Q4 2025 respectively.